Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole
Pharmaceutics · 23.03.2023 · 15 (4) · 1040
DOI: 10.3390/pharmaceutics15041040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.03.2023. Verfasst von Harsh Shah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Invagen, A Cipla Subsidiary, Hauppauge, NY 11788, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Albendazole (ABZ) is a weakly basic drug that undergoes extensive presystemic metabolism after oral administration and converts to its active form albendazole sulfoxide (ABZ_SO). The absorption of albendazole is limited by poor aqueous solubility, and dissolution is the rate-limiting step in the overall exposure of ABZ_SO. In this study, PBPK modeling was used to identify formulation-specific parameters that impact the oral bioavailability of ABZ_SO. In vitro experiments were carried out to determine pH solubility, precipitation kinetics, particle size distribution, and biorelevant solubility. A transfer experiment was conducted to determine the precipitation kinetics. A PBPK model for ABZ and ABZ_SO was developed using the Simcyp™ Simulator based on parameter estimates from in vitro experiments. Sensitivity analyses were performed to assess the impact of physiological parameters and formulation-related parameters on the systemic exposure of ABZ_SO. Model simulations predicted that increased gastric pH significantly reduced ABZ absorption and, subsequently, ABZ_SO systemic exposure. Reducing the particle size below 50 µm did not improve the bioavailability of ABZ. Modeling results illustrated that systemic exposure of ABZ_SO was enhanced by increasing solubility or supersaturation and decreasing the drug precipitation of ABZ at the intestinal pH level. These results were used to identify potential formulation strategies to enhance the oral bioavailability of ABZ_SO.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Invagen, A Cipla Subsidiary, Hauppauge, NY 11788, USA.
- Takeda Pharmaceuticals International Inc., Cambridge, MA 02139, USA.
- Impel NeuroPharma, Seattle, WA 98119, USA.
- Division of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA.
- Samuel J. and Joan B. Williamson Institute for Pharmacometrics, Division of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA.
ORCID-Profile: Kushal Shah, David R Taft
Zitieren
APA
Shah, H., Shah, K., Gajera, B., Dave, R. H., & Taft, D. R. (2023). Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole. Pharmaceutics, 15(4), 1040. https://doi.org/10.3390/pharmaceutics15041040
Vancouver
Shah H, Shah K, Gajera B, Dave RH, Taft DR. Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole. Pharmaceutics. 2023;15(4):1040. doi:10.3390/pharmaceutics15041040
BibTeX
@article{Shah2023,
author = {Shah, Harsh and Shah, Kushal and Gajera, Bhavin and Dave, Rutesh H and Taft, David R},
title = {Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {4},
pages = {1040},
doi = {10.3390/pharmaceutics15041040}
}
EUVIMED